GW Pharmaceuticals GWP Notice of Results

  GW Pharmaceuticals (GWP) - Notice of Results

RNS Number : 7909R
GW Pharmaceuticals PLC
22 November 2012




                            GW Pharmaceuticals plc

                                      

                           Notification of Results

                                      

Porton Down,UK;22November 2012:GW Pharmaceuticals  plc (AIM: GWP) will  be 
announcing its Preliminary financial results  for the year ended 30  September 
2012, on Wednesday 28 November 2012.



                                    -ends-



Enquiries:



FTI Consulting                          + 44 20 7831 3113
Ben Atwell / John Dineen / Simon Conway





Notes to Editors



About GW

GW was founded in  1998 and listed on  the AIM, a market  of the London  Stock 
Exchange, in June 2001. Operating under  license from the UK Home Office,  the 
company  researches  and  develops  cannabinoid  pharmaceutical  products  for 
patients who suffer from a range  of serious ailments, in particular  multiple 
sclerosis and cancer pain. GW has  assembled a large in-house scientific  team 
with expertise in cannabinoid science as well as experience in the development
of  both  plant-based  prescription  pharmaceutical  products  and   medicines 
containing controlled  substances. GW  occupies a  world leading  position  in 
cannabinoids and has developed an extensive international network of the  most 
prominent scientists  in  the field.  For  further information,  please  visit 
www.gwpharm.com



                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


NORFLLFLLFFLFBK -0- Nov/22/2012 11:31 GMT